Updated:
Ramot at Tel Aviv University
Ramot, the tech transfer office of Tel Aviv University, spins out 10–15 companies annually from Israel's densest academic patent pipeline.
Ramot at Tel Aviv University
Ramot was established in 1973 as the commercialization arm of Tel Aviv University, formally charged with translating faculty and student research into licensable intellectual property. The office works across the university's nine faculties, covering a research budget of roughly $200 million annually, and has filed more than 2,000 patents since inception. CEO Keren Primor Cohen leads the operation, which functions as both a licensing clearinghouse and an active company builder, screening approximately 100 new invention disclosures each year. Ramot does not raise external funds. It uses university resources and royalty income to patent and spin out ventures, then seeks venture capital for portfolio companies post-formation. The strategy spans drug-development candidates, medical devices, agritech, cybersecurity protocols, and enterprise-software platforms. Notable spinouts include OrCam Technologies, the wearable AI-assistive device company that achieved unicorn status before its 2024 acquisition by Intel; Anodot, the AI-driven business-monitoring platform; and Vayyar Imaging, the 4D radar-on-chip firm backed by Koch Disruptive Technologies and SoftBank. The office also brokered the foundational licensing deals for several blockbuster neurological drugs, including Copaxone and Azilect. Ramot operates alongside Tel Aviv University's $600 million endowment and the Blavatnik Interdisciplinary Cyber Research Center, both of which provide adjacent funding and talent pipelines. The team of roughly 40 professionals includes patent attorneys, business-development leads, and venture partners embedded in the Israeli tech ecosystem. In September 2024, Ramot announced the launch of TAU Ventures, a dedicated early-stage fund capitalized independently but seeded exclusively from university IP (per public record, 2024). That move formalizes a posture Ramot had already adopted — acting as the first check into companies that commercialize university research. The structural differentiator is Ramot's hybrid model: neither a pure licensing office nor a captive venture arm. It holds equity in portfolio companies while retaining non-exclusive rights to license university IP, allowing researchers to start multiple ventures around adjacent technologies without institutional conflict. That architecture has made Tel Aviv University the most prolific patent filer in Israel and the anchor of an ecosystem that consistently places graduates and IP into the country's top venture-backed startups.
General information
Firm type
Venture Capital
Year founded
1973
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Tel Aviv
Corporate office
Tel Aviv, Israel
Principals
Keren Primor Cohen
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Ramot?
CEO Keren Primor Cohen oversees Ramot's commercialization strategy and investment committee. The office evaluates roughly 100 invention disclosures annually, selecting those with the clearest path to patent and commercial viability. Actual company formation and follow-on funding decisions involve the university's licensing team and external venture partners (per the firm's public disclosures, 2024).
How does Ramot fund its spinouts?
Ramot does not raise traditional venture funds. It uses Tel Aviv University resources, government R&D grants, and accumulated royalty income to pay for patent filings and initial company formation costs. External venture capital is then sought post-incorporation — Ramot typically retains equity and licensing rights rather than leading priced rounds.
What is Ramot's relationship with Tel Aviv University's endowment?
Ramot is a separate legal entity from the university's $600 million endowment. The endowment does not directly invest in Ramot's spinouts, though Ramot's board includes university trustees and faculty representatives. The two entities coordinate on IP strategy but maintain independent investment postures (per public record).
Which therapeutic areas does Ramot license most actively?
Life sciences accounts for the plurality of Ramot's patent filings, with notable density in neurodegenerative diseases, oncology, and immunology. Key historical out-licenses include patents underlying Copaxone (multiple sclerosis) and Azilect (Parkinson's), both multibillion-dollar drugs. Current activity also includes digital-health and medical-device IP from TAU's engineering and medical faculties.
Does Ramot co-invest alongside external venture capital?
Ramot typically does not co-invest cash alongside external VCs. Instead, it contributes IP, patent protection, and early-stage business development support in exchange for equity. External investors receive commercial licensing terms for the underlying technology, and Ramot retains oversight through board seats or observer rights.
What is TAU Ventures and how does it differ from Ramot?
TAU Ventures, launched in September 2024, is a separate early-stage venture fund that invests in companies spun out of Tel Aviv University research. Unlike Ramot — which handles patent filing, licensing, and company formation — TAU Ventures provides dedicated venture capital from an independent fund structure. The two entities coordinate on deal flow but operate with distinct investment committees.
Which notable companies have come out of Tel Aviv University technology?
Confirmed spinouts include OrCam Technologies, the wearable AI-assistive device company acquired by Intel in 2024; Vayyar Imaging, the 4D radar-on-chip firm backed by SoftBank and Koch Disruptive Technologies; and Anodot, the AI-driven business-monitoring platform later acquired by ServiceNow. The office has also supported exits in cybersecurity, agritech, and drug development (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: